Biopharma deal-making activity, a closely watched marker of industry health, was alive and well in the second quarter. BioWorld Senior Analyst Karen Carey sifts through the numbers.   Hosted on Acast. See <a style="color: grey;" href="https://acast.com/privacy" target= "_blank" rel="noopener noreferrer">acast.com/privacy</a> for more information.

Biopharma deal-making activity, a closely watched marker of industry health, was alive and well in the second quarter. BioWorld Senior Analyst Karen Carey sifts through the numbers. Hosted on Acast. See acast.com/privacy for more information.

Biopharma deal-making activity, a closely watched marker of industry health, was alive and well in the second quarter. BioWorld Senior Analyst Karen Carey sifts through the numbers. &nbsp; Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer">acast.com/privacy</a> for more information.

As biopharma deals keep pace, M&A volumes languish

One-on-one with medical innovators: Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us for a new conversation.

Share As biopharma deals keep pace, M&A volumes languish

Sign up to save your podcasts

As biopharma deals keep pace, M&A volumes languish

As biopharma deals keep pace, M&A volumes languish